No more than 15 authors can be listed.Please ensure the authors are listed in the right order.If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.
Inorganic arsenic in groundwater is a major environmental health crisis, affecting an estimated 94–220 million people globally, predominantly in South and Southeast Asia. Other sources include crops irrigated with arsenic-rich water and treated with arsenic-enriched pesticides, industrial waste, and tobacco. Arsenic is a Group 1 human carcinogen linked to lung, skin and bladder cancers, with persistence of risk for decades after exposure cessation. Cutaneous signs of chronic arsenicosis serve as clinical risk indicators for subsequent malignancy.
A 60-year-old woman presented with cough, dyspnea, and weight loss for three months. Examination revealed classic cutaneous stigmata of chronic arsenicosis: hyperkeratosis of the soles, hyperkeratotic papules on the palms and soles, diffuse hypopigmented lesions, and irregularly hyperpigmented maculopapular lesions with irregular margins over the back and legs. She had a history of arsenic exposure through groundwater from tube wells approximately 15 years prior, lasting 4-5 years. CT chest demonstrated a cavitary lesion in the left lower lobe. PET-CT revealed an intensely FDG-avid lesion with irregular margins in the left lower lobe with a non-avid centre and mildly avid mediastinal lymph nodes. Biopsy from the lesion wall confirmed non-small cell lung carcinoma with an unusual biphenotypic immunoprofile (P40 and napsin A positive; CK7, CK20, ALK, and EGFR negative), suggesting a poorly differentiated tumor. Skin examination revealed suspicious lesions warranting biopsy for potential concurrent cutaneous malignancy. The patient finally opted for palliative therapy.
This case illustrates the prolonged latency of arsenic-induced carcinogenesis. The unusual lung tumor immunoprofile highlights the importance of molecular characterization in arsenic-associated malignancies. Clinicians encountering arsenic-related malignancy should systematically screen for concurrent cancers at other arsenic-target sites. This case underscores the need for an integrated program of multi-site cancer surveillance in populations with chronic arsenicosis.